NCT00973479 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 197
- group Id
- BG001
- value
- 395
- group Id
- BG002
- value
- 592
- units
- Participants
- groups
- description
- Participants randomized to receive their stable dose of commercial MTX (between 15-25 mg/week) and placebo IV infusions at Weeks 0, 4, 12, 16, and 20. Participants will be crossed over to Golimumab 2 mg/kg at Week 24, and receive administrations at Weeks 24, 28 and q8 weeks thereafter up to Week 100. Subjects randomized to Group I (Placebo + MTX) will have the opportunity to enter early escape at Week 16 and initiate Golimumab 2 mg/kg infusions (Weeks 16, 20, and q8 weeks up to Week 100) if they demonstrate a \< 10% improvement in both tender and swollen joint count.
- id
- BG000
- title
- Group I: Placebo + Methotrexate (MTX)
- description
- Participants randomized to receive 2 mg/kg of Golimumab intravenously at Weeks 0, 4, and q8 weeks up to Week 100. Participants will be maintained on their stable dose of commercial MTX (between 15 and 25 mg/week) throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
- id
- BG001
- title
- Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.26
- value
- 51.4
- group Id
- BG001
- spread
- 12.55
- value
- 51.9
- group Id
- BG002
- spread
- 12.13
- value
- 51.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 157
- group Id
- BG001
- value
- 326
- group Id
- BG002
- value
- 483
- title
- Female
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 69
- group Id
- BG002
- value
- 109
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 82
- title
- Argentina
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 9
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 37
- title
- Columbia
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 31
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 16
- title
- Korea, Republic of
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 64
- title
- Lithuania
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 26
- title
- Malaysia
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 38
- title
- Mexico
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 6
- title
- New Zealand
- categories
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 101
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 69
- title
- Russian Federation
- categories
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 58
- group Id
- BG002
- value
- 90
- title
- Ukraine
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 197
- group Id
- BG001
- value
- 395
- group Id
- BG002
- value
- 592
- units
- Participants
- groups
- description
- Participants randomized to receive their stable dose of commercial MTX (between 15-25 mg/week) and placebo IV infusions at Weeks 0, 4, 12, 16, and 20. Participants will be crossed over to Golimumab 2 mg/kg at Week 24, and receive administrations at Weeks 24, 28 and q8 weeks thereafter up to Week 100. Subjects randomized to Group I (Placebo + MTX) will have the opportunity to enter early escape at Week 16 and initiate Golimumab 2 mg/kg infusions (Weeks 16, 20, and q8 weeks up to Week 100) if they demonstrate a \< 10% improvement in both tender and swollen joint count.
- id
- BG000
- title
- Group I: Placebo + Methotrexate (MTX)
- description
- Participants randomized to receive 2 mg/kg of Golimumab intravenously at Weeks 0, 4, and q8 weeks up to Week 100. Participants will be maintained on their stable dose of commercial MTX (between 15 and 25 mg/week) throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
- id
- BG001
- title
- Group II: Golimumab 2 mg/kg + Methotrexate (MTX)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.26
- value
- 51.4
- group Id
- BG001
- spread
- 12.55
- value
- 51.9
- group Id
- BG002
- spread
- 12.13
- value
- 51.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 157
- group Id
- BG001
- value
- 326
- group Id
- BG002
- value
- 483
- title
- Female
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 69
- group Id
- BG002
- value
- 109
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 82
- title
- Argentina
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 9
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 37
- title
- Columbia
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 31
- title
- Hungary
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 16
- title
- Korea, Republic of
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 64
- title
- Lithuania
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 26
- title
- Malaysia
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 38
- title
- Mexico
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 6
- title
- New Zealand
- categories
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 101
- title
- Poland
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 69
- title
- Russian Federation
- categories
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 58
- group Id
- BG002
- value
- 90
- title
- Ukraine
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle